Talazoparib in Treating Patients With Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations in the BRCA Genes

NCT02286687 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

150

Enrollment

OTHER

Sponsor class

Conditions

Advanced Malignant Neoplasm
ATM Gene Mutation
BRCA1 Gene Mutation
BRCA2 Gene Mutation
Metastatic Malignant Neoplasm
PALB2 Gene Mutation
Recurrent Malignant Neoplasm
Refractory Malignant Neoplasm

Interventions

OTHER: Laboratory Biomarker Analysis
OTHER: Pharmacological Study
DRUG: Talazoparib

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]